NCT07195318

Fisetin Supplementation for Healthy Aging

Low-dose Fisetin Supplementation for Healthy Aging - a Triple-blind, Randomized, Placebo-controlled Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Ove Andersen · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Accepted

Summary

There is growing interest among the general population in preventive health interventions that can help mitigate age-related decline, reduce the risk of chronic diseases, and promote healthy aging. The use of nutritional supplements has been increasing and is especially high in older adults and healthier individuals. In response to this demand, a growing number of nutritional supplements are being advertised for their "anti-aging" properties, claiming to target molecular and cellular "hallmarks of aging", such as chronic inflammation, oxidative stress, and cellular senescence. However, the overwhelming majority of these claims stem from preclinical studies in animal models (e.g., C. elegans, mice), and there is extremely limited evidence for beneficial effects, effective doses, or safety profiles of these supplements in humans. Moreover, the lack of strict regulations in the nutritional supplement industry leads to wide differences in the quality and in the actual content of active substances between supplements, which could impact both their efficacy and safety. The investigators will conduct a clinical trial in healthy volunteers, who will receive supplementation with fisetin (100 mg) or placebo daily for 7 weeks. Participants will be examined at regular intervals during the study period. The investigators will then investigate whether fisetin supplementation is safe and evaluate its effect on measures of chronic inflammation, cellular senescence, aging, and general health.

Detailed description

The goal of this study is to assess the anti-inflammatory effects, overall health benefits, and the safety of a daily low dose (100 mg) of fisetin in relatively healthy middle-aged and older adults. The study is a 2-arm triple-blind randomized placebo-controlled trial, in which middle-aged and older adults (n=120) will receive either: * One capsule (100 mg) fisetin daily for 7 weeks (intervention group), or * One capsule placebo daily for 7 weeks (control group).

Conditions

• Healthy

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Fisetin	One capsule (100 mg) daily
DIETARY_SUPPLEMENT	Placebo	One capsule daily

Timeline

• Start date: 2025-09-24
• Primary completion: 2026-10-31
• Completion: 2035-09-20
• First posted: 2025-09-26
• Last updated: 2025-11-20

Locations

1 site across 1 country: Denmark